Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy

Figure 1 Flow chart depicting the screening of hepatocellular cancer patients who received camrelizumab combined with lenvatinib. PD-1: Programmed cell death protein-1; PD-L1: Programmed death ligand-1; TyG: Triglyceride-glucose.

Figure 2 Effects of different triglyceride-glucose indexes on the long-term prognosis of hepatocellular cancer patients. A: Kaplan-Meier plot of in the triglyceride-glucose (TyG) index < 1.58 and TyG index ≥ 1.58 groups; B: Kaplan-Meier plot of overall survival in the TyG index < 1.58 and TyG index ≥ 1.58 groups. TyG: Triglyceride-glucose; HR: Hazard ratio; CI: Confidence interval.

Figure 3 Graph depicting the prognostic model for predicting 12-, 15-, and 18-month overall survival. ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; TyG: Triglyceride-glucose; OS: Overall survival.

Figure 4 Graph depicting the operating characteristic evaluation plot for a prognostic model. A: Graph showing the training set and validation set receiver operating characteristic (ROC) evaluation plots for 12-month prognostic prediction model; B: Graph showing the training set and validation set ROC evaluation plots for 15-month prognostic prediction model; C: Graph showing the training set and validation set ROC evaluation plots for 18-month prognostic prediction model. AUC: Area under the curve; CI: Confidence interval.

Figure 5 Graph illustrating the calibration plots for a prognostic model. A: Calibration plots for the training set 12-month overall survival (OS); B: Calibration plots for the validation set 12-month OS; C: Calibration plots for the training set 15-month OS; D: Calibration plots for the validation set 15-month OS; E: Calibration plots for the training set 18-month OS; F: Calibration plots for validation set 18-month OS.